{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:34:19Z","timestamp":1793064859764,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-NCJH202201-0049"],"award-info":[{"award-number":["Y-NCJH202201-0049"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41417-026-01078-9","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:32:19Z","timestamp":1787837539000},"page":"1201-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8+ T cells"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-9567","authenticated-orcid":false,"given":"Chunli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigmat","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingtong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-3389","authenticated-orcid":false,"given":"Weilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-2489","authenticated-orcid":false,"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"1078_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10:45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"key":"1078_CR2","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","volume":"33","author":"AH Bazarbachi","year":"2019","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Harousseau J-L, Mohty M. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33:2343\u201357. https:\/\/doi.org\/10.1038\/s41375-019-0561-2.","journal-title":"Leukemia"},{"key":"1078_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1903455.","journal-title":"N Engl J Med"},{"key":"1078_CR4","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396:1563\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(20)32292-3.","journal-title":"Lancet"},{"key":"1078_CR5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s00277-024-05615-0","volume":"103","author":"JH Yi","year":"2024","unstructured":"Yi JH, Park S-S, Min C-K, Eom H-S, Byun JM, Koh Y, et al. Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis. Ann Hematol. 2024;103:2365\u201372. https:\/\/doi.org\/10.1007\/s00277-024-05615-0.","journal-title":"Ann Hematol"},{"key":"1078_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02305-4","volume":"20","author":"L Qiu","year":"2022","unstructured":"Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, et al. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med. 2022;20:108. https:\/\/doi.org\/10.1186\/s12916-022-02305-4.","journal-title":"BMC Med"},{"key":"1078_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2023;21:1281\u2013301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061.","journal-title":"J Natl Compr Cancer Netw"},{"key":"1078_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2024","unstructured":"Rafae A, van Rhee F, Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist. 2024;29:200\u201312. https:\/\/doi.org\/10.1093\/oncolo\/oyad306.","journal-title":"Oncologist"},{"key":"1078_CR9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.3324\/haematol.2023.284089","volume":"109","author":"V Gonz\u00e1lez-Calle","year":"2024","unstructured":"Gonz\u00e1lez-Calle V, Rodr\u00edguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, et al. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study. haematol. 2024;109:2219\u201328. https:\/\/doi.org\/10.3324\/haematol.2023.284089.","journal-title":"haematol"},{"key":"1078_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"P Rodriguez-Otero","year":"2021","unstructured":"Rodriguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021;100:102284. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102284.","journal-title":"Cancer Treat Rev"},{"key":"1078_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275329","volume":"14","author":"AF Binder","year":"2023","unstructured":"Binder AF, Walker CJ, Mark TM, Baljevic M. Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors. Front Immunol. 2023;14:1275329. https:\/\/doi.org\/10.3389\/fimmu.2023.1275329.","journal-title":"Front Immunol"},{"key":"1078_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1158\/0008-5472.Can-22-2553","volume":"83","author":"EY Faraoni","year":"2023","unstructured":"Faraoni EY, Singh K, Chandra V, Le Roux O, Dai Y, Sahin I, et al. CD73-dependent adenosine signaling through Adora2b drives immunosuppression in ductal pancreatic cancer. Cancer Res. 2023;83:1111\u201327. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-2553.","journal-title":"Cancer Res"},{"key":"1078_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206335","volume":"10","author":"W Liu","year":"2023","unstructured":"Liu W, Yu X, Yuan Y, Feng Y, Wu C, Huang C, et al. CD73, a promising therapeutic target of diclofenac, promotes metastasis of pancreatic cancer through a nucleotidase-independent mechanism. Adv Sci. 2023;10:2206335. https:\/\/doi.org\/10.1002\/advs.202206335.","journal-title":"Adv Sci"},{"key":"1078_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jid.2022.12.003","volume":"143","author":"M Da","year":"2023","unstructured":"Da M, Chen L, Enk A, Mahnke K. Tolerance to 2,4-dinitrofluorobenzene\u2012induced contact hypersensitivity is mediated by CD73-expressing tissue-homing regulatory T cells. J Investig Dermatol. 2023;143:1011\u20131022.e1018. https:\/\/doi.org\/10.1016\/j.jid.2022.12.003.","journal-title":"J Investig Dermatol"},{"key":"1078_CR15","doi-asserted-by":"publisher","first-page":"e004114","DOI":"10.1136\/jitc-2021-004114","volume":"10","author":"T Zhang","year":"2022","unstructured":"Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L, et al. Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL. J Immunother Cancer. 2022;10:e004114. https:\/\/doi.org\/10.1136\/jitc-2021-004114.","journal-title":"J Immunother Cancer"},{"key":"1078_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41577-020-0376-4","volume":"20","author":"AK Moesta","year":"2020","unstructured":"Moesta AK, Li X-Y, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020;20:739\u201355. https:\/\/doi.org\/10.1038\/s41577-020-0376-4.","journal-title":"Nat Rev Immunol"},{"key":"1078_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100988","volume":"70","author":"W Jia","year":"2023","unstructured":"Jia W, Huang Z, Zhou L, Liou Y-C, Di Virgilio F, Ulrich H, et al. Purinergic signalling in cancer therapeutic resistance: from mechanisms to targeting strategies. Drug Resist Updates. 2023;70:100988. https:\/\/doi.org\/10.1016\/j.drup.2023.100988.","journal-title":"Drug Resist Updates"},{"key":"1078_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","volume":"53","author":"M Roh","year":"2020","unstructured":"Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol. 2020;53:66\u201376. https:\/\/doi.org\/10.1016\/j.coph.2020.07.001.","journal-title":"Curr Opin Pharmacol"},{"key":"1078_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/imt-2018-0200","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, et al. Cd73: an emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019;11:983\u201397. https:\/\/doi.org\/10.2217\/imt-2018-0200.","journal-title":"Immunotherapy"},{"key":"1078_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3128-5","volume":"17","author":"Z-w Gao","year":"2017","unstructured":"Gao Z-w, Wang H-p, Lin F, Wang X, Long M, Zhang H-Z, et al. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity. BMC Cancer. 2017;17:135. https:\/\/doi.org\/10.1186\/s12885-017-3128-5.","journal-title":"BMC Cancer"},{"key":"1078_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hask\u00f3 G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355\u201367. https:\/\/doi.org\/10.1016\/j.molmed.2013.03.005.","journal-title":"Trends Mol Med"},{"key":"1078_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GXY Zheng","year":"2017","unstructured":"Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049. https:\/\/doi.org\/10.1038\/ncomms14049.","journal-title":"Nat Commun"},{"key":"1078_CR23","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387.e3529. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048.","journal-title":"Cell"},{"key":"1078_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, et al. Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017;14:979\u201382. https:\/\/doi.org\/10.1038\/nmeth.4402.","journal-title":"Nat Methods"},{"key":"1078_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566:496\u2013502. https:\/\/doi.org\/10.1038\/s41586-019-0969-x.","journal-title":"Nature"},{"key":"1078_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati GS, Sikandar SS, Wesche DJ, Manjunath A, Bharadwaj A, Berger MJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020;367:405\u201311. https:\/\/doi.org\/10.1126\/science.aax0249.","journal-title":"Science"},{"key":"1078_CR27","unstructured":"Tickle T, Tirosh I, Georgescu C, Brown M, Haas B. InferCNV of the Trinity CTAT Project. Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. https:\/\/github.com\/broadinstitute\/inferCNV (2019)."},{"key":"1078_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2024","unstructured":"Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell\u2013cell communication from single-cell transcriptomics. Nat Protoc. 2024;20:180\u2013219. https:\/\/doi.org\/10.1038\/s41596-024-01045-4.","journal-title":"Nat Protoc"},{"key":"1078_CR29","doi-asserted-by":"publisher","first-page":"e1003323","DOI":"10.1371\/journal.pmed.1003323","volume":"17","author":"SA Danziger","year":"2020","unstructured":"Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, et al. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the Total Therapy clinical trials. PLoS Med. 2020;17:e1003323. https:\/\/doi.org\/10.1371\/journal.pmed.1003323.","journal-title":"PLoS Med"},{"key":"1078_CR30","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cancers12092397","volume":"12","author":"EK Cotul","year":"2020","unstructured":"Cotul EK, Zuo Q, Santaliz-Casiano A, Imir OB, Mogol AN, Tunc E, et al. Combined targeting of estrogen receptor alpha and exportin 1 in metastatic breast cancers. Cancers. 2020;12:2397. https:\/\/doi.org\/10.3390\/cancers12092397.","journal-title":"Cancers"},{"key":"1078_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1158\/0008-5472.Can-23-1992","volume":"84","author":"R Marullo","year":"2024","unstructured":"Marullo R, Rutherford SC, Revuelta MV, Zamponi N, Culjkovic-Kraljacic B, Kotlov N, et al. XPO1 enables adaptive regulation of mRNA export required for genotoxic stress tolerance in cancer cells. Cancer Res. 2024;84:101\u201317. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-1992.","journal-title":"Cancer Res"},{"key":"1078_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf7006","volume":"15","author":"A Quintanal-Villalonga","year":"2023","unstructured":"Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. 2023;15:eadf7006. https:\/\/doi.org\/10.1126\/scitranslmed.adf7006.","journal-title":"Sci Transl Med"},{"key":"1078_CR33","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.1182\/bloodadvances.2022007563","volume":"6","author":"G Pianigiani","year":"2022","unstructured":"Pianigiani G, Gagliardi A, Mezzasoma F, Rocchio F, Tini V, Bigerna B, et al. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML. Blood Adv. 2022;6:5938\u201349. https:\/\/doi.org\/10.1182\/bloodadvances.2022007563.","journal-title":"Blood Adv"},{"key":"1078_CR34","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28:1212\u201323. https:\/\/doi.org\/10.1038\/s41591-022-01819-x.","journal-title":"Nat Med"},{"key":"1078_CR35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.medj.2022.09.002","volume":"3","author":"DF Coutinho","year":"2022","unstructured":"Coutinho DF, Mundi PS, Marks LJ, Burke C, Ortiz MV, Diolaiti D, et al. Validation of a non-oncogene-encoded vulnerability to exportin 1 inhibition in pediatric renal tumors. Med. 2022;3:774\u201391.e777. https:\/\/doi.org\/10.1016\/j.medj.2022.09.002.","journal-title":"Med"},{"key":"1078_CR36","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.Cd-22-0424","volume":"13","author":"XQD Wang","year":"2023","unstructured":"Wang XQD, Fan D, Han Q, Liu Y, Miao H, Wang X, et al. Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia. Cancer Discov. 2023;13:724\u201345. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0424.","journal-title":"Cancer Discov"},{"key":"1078_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s43018-022-00394-x","volume":"3","author":"KH Lin","year":"2022","unstructured":"Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, et al. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat Cancer. 2022;3:837\u201351. https:\/\/doi.org\/10.1038\/s43018-022-00394-x.","journal-title":"Nat Cancer"},{"key":"1078_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"key":"1078_CR39","doi-asserted-by":"publisher","unstructured":"Kotecha N, Krutzik PO, Irish JM. Web-based analysis and publication of flow cytometry experiments. CP Cytometry 53, Unit10.17. 2010. https:\/\/doi.org\/10.1002\/0471142956.cy1017s53","DOI":"10.1002\/0471142956.cy1017s53"},{"key":"1078_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17:611\u201329. https:\/\/doi.org\/10.1038\/s41571-020-0382-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1078_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01019-5","volume":"14","author":"A Ray","year":"2024","unstructured":"Ray A, Du T, Wan X, Song Y, Pillai SC, Musa MA, et al. A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death. Blood Cancer J. 2024;14:58. https:\/\/doi.org\/10.1038\/s41408-024-01019-5.","journal-title":"Blood Cancer J"},{"key":"1078_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi0244","volume":"9","author":"R Samain","year":"2023","unstructured":"Samain R, Maiques O, Monger J, Lam H, Candido J, George S, et al. CD73 controls Myosin II\u2013driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells. Sci Adv. 2023;9:eadi0244. https:\/\/doi.org\/10.1126\/sciadv.adi0244.","journal-title":"Sci Adv"},{"key":"1078_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12218","volume":"11","author":"T Lu","year":"2022","unstructured":"Lu T, Zhang Z, Zhang J, Pan X, Zhu X, Wang X, et al. CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment. J Extracell Vesicle. 2022;11:e12218. https:\/\/doi.org\/10.1002\/jev2.12218.","journal-title":"J Extracell Vesicle"},{"key":"1078_CR44","doi-asserted-by":"publisher","first-page":"e006842","DOI":"10.1136\/jitc-2023-006842","volume":"11","author":"J Ye","year":"2023","unstructured":"Ye J, Gavras NW, Keeley DC, Hughson AL, Hannon G, Vrooman TG, et al. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models. J Immunother Cancer. 2023;11:e006842. https:\/\/doi.org\/10.1136\/jitc-2023-006842.","journal-title":"J Immunother Cancer"},{"key":"1078_CR45","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, LoRusso P, Overman M, Noonan AM, Kim D-W, Strickler JH, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023;72:2443\u201358. https:\/\/doi.org\/10.1007\/s00262-023-03430-6.","journal-title":"Cancer Immunol Immunother"},{"key":"1078_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22:44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x.","journal-title":"Mol Cancer"},{"key":"1078_CR47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","volume":"57","author":"KP Burke","year":"2024","unstructured":"Burke KP, Chaudhri A, Freeman GJ, Sharpe AH. The B7:CD28 family and friends: unraveling coinhibitory interactions. Immunity. 2024;57:223\u201344. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.013.","journal-title":"Immunity"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01078-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01078-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:05:06Z","timestamp":1793063106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01078-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01078-9","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The protocol and any amendments or procedures involving the care and use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio prior to execution. During the study, the care and use of animals were conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}